Technical Director, Clinical Chemistry
Clinical chemistry laboratory services, molecular pathophysiology
Hemoglobinopathies, cancer markers, newborn screening, endocrine disease testing, preanalytical interferences, gene expression and regulation, molecular mechanisms of gene transcription and their involvement in disease development
Education and Training
B.Sc., Biochemistry, Cum Laude, "King Al. I Cuza" University, Iasi, Romania, 2001
M.Sc., Molecular Biology, Department of Physiology, University of Manitoba, Winnipeg, Manitoba, Canada, 2006
Ph.D., Molecular Biology, Department of Physiology, University of Manitoba, Winnipeg, Manitoba, Canada, 2010
Clinical Chemistry & Toxicology Fellowship, Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, South Carolina, USA, 2012
Sofronescu AG, Loebs T, Zhu Y. Effects of temperature and light on the stability of bilirubin in plasma samples. Clin Chim Acta. 2012 Feb18;413(3-4):463-6. PubMed PMID: 22108388.
Sofronescu AG, Williams LM, Andrews DM, Zhu Y. Unexpected hemoglobin A1cresults. Clin Chem. 2011 Feb;57(2):153-6. PubMed PMID: 21278358.
Sofronescu AG, Detillieux KA, Cattini PA. FGF-16 is a target for adrenergic stimulation through NF-kappaB activation in postnatal cardiac cells and adult mouse heart. Cardiovasc Res. 2010 Jul 1;87(1):102-10.PubMedPMID: 20097674.
Sofronescu AG, Jin Y, Cattini PA. A myocyte enhancer factor 2 (MEF2) site located in a hypersensitive region of the FGF16 gene locus is required for preferential promoter activity in neonatal cardiac myocytes. DNA Cell Biol. 2008 Apr;27(4):173-82. PubMed PMID: 18260768.